Adimmune to shift vaccine research to focus on new COVID-19 variants

02/17/2021 09:19 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Taipei, Feb. 17 (CNA) Taiwan's Adimmune Corp., which has fallen behind two other domestic pharmaceutical firms in the race to roll out a COVID-19 vaccine, said Wednesday that it will shift its focus to developing vaccines targeting new variants of the virus.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.